|
|||||
|
|
Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation |
|
| Authors: | Nicoletta Cieri Sara Mastaglio Giacomo Oliveira Monica Casucci Attilio Bondanza Chiara Bonini |
| Affiliation: | 1. University Vita-Salute San Raffaele, Milan, Italy Experimental Hematology Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy, PIBIC, San Raffaele Scientific Institute, Milan, Italy;2. Experimental Hematology Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy, PIBIC, San Raffaele Scientific Institute, Milan, Italy;3. Experimental Hematology Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy, PIBIC, San Raffaele Scientific Institute, Milan, Italy Correspondence to: Chiara Bonini Experimental Hematology Unit San Raffaele Scientific Institute via Olgettina 60 Milano 20131, Italy Tel.: +390226434790 Fax: +390226434790 e-mail: bonini.chiara@hsr.it |
| Abstract: | Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. |
| Keywords: | allogeneic hematopoietic stem cell transplantation adoptive cellular immunotherapy gene therapy suicide gene TCR CAR |